Campbell & CO Investment Adviser LLC Has $251,000 Position in NeoGenomics, Inc. (NASDAQ:NEO)
Campbell & CO Investment Adviser LLC cut its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 52.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,442 shares of the medical research company’s stock after selling 12,420 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in NeoGenomics were worth $251,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. American Century Companies Inc. boosted its holdings in NeoGenomics by 123.5% in the 4th quarter. American Century Companies Inc. now owns 687,775 shares of the medical research company’s stock valued at $8,673,000 after purchasing an additional 380,041 shares in the last quarter. Suntrust Banks Inc. boosted its holdings in NeoGenomics by 2.6% in the 4th quarter. Suntrust Banks Inc. now owns 39,959 shares of the medical research company’s stock valued at $504,000 after purchasing an additional 1,028 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in NeoGenomics in the 1st quarter valued at approximately $652,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in NeoGenomics in the 1st quarter valued at approximately $664,000. Finally, Dimensional Fund Advisors LP boosted its holdings in NeoGenomics by 17.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,138,241 shares of the medical research company’s stock valued at $14,352,000 after purchasing an additional 172,451 shares in the last quarter. Hedge funds and other institutional investors own 79.00% of the company’s stock.
A number of equities research analysts have weighed in on NEO shares. Zacks Investment Research lowered NeoGenomics from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Raymond James boosted their price target on NeoGenomics from $23.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 31st. Benchmark set a $27.00 price target on NeoGenomics and gave the stock a “buy” rating in a research note on Wednesday, July 31st. BidaskClub raised NeoGenomics from a “hold” rating to a “buy” rating in a research note on Friday, July 19th. Finally, ValuEngine lowered NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $23.78.
NEO traded up $0.27 during trading on Monday, hitting $25.51. The company’s stock had a trading volume of 1,058,100 shares, compared to its average volume of 1,070,342. The firm’s 50 day moving average price is $23.98 and its 200-day moving average price is $21.42. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.67 and a quick ratio of 4.52. The stock has a market cap of $2.67 billion, a PE ratio of 196.23 and a beta of 0.96. NeoGenomics, Inc. has a twelve month low of $11.05 and a twelve month high of $26.89.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.02. The company had revenue of $101.71 million during the quarter, compared to the consensus estimate of $97.32 million. NeoGenomics had a return on equity of 4.97% and a net margin of 0.57%. NeoGenomics’s revenue was up 50.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.05 EPS. Equities analysts anticipate that NeoGenomics, Inc. will post 0.18 earnings per share for the current year.
NeoGenomics Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source